Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
Completed · Phase 4
Conditions studied: Chemotherapy-induced Nausea and Vomiting
In brief
The purpose of this study is to evaluate the safety and tolerability of a 3-day intravenous (IV) fosaprepitant dimeglumine (MK-0517) regimen for the prevention of CINV in pediatric participants scheduled to receive emetogenic chemotherapy. Each participant was enrolled in Cycle 1 (on which the primary study objectives were based), consisting of the 3-day treatment cycle and 14 days of follow-up for a total of 17 days.
Key facts
- Study ID
- NCT04054193
- Run by
- Merck Sharp & Dohme LLC
- People needed
- 103
- Starts
- 2019-09-09
- Expected to finish
- 2021-02-11
- Last updated by the study team
- 2025-01-16
Who can join
Age: 1 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Is receiving a moderately or highly emetogenic chemotherapy agent/regimen or a chemotherapy agent/regimen not previously tolerated due to vomiting
- Has a Lansky Play Performance score ≥60 (participants ≤16 years of age) or a Karnofsky score ≥60 (participants >16 years of age)
- Has a pre-existing functional central venous catheter available for study treatment administration
- Is fosaprepitant naïve
- Has a predicted life expectancy ≥3 months
- A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of childbearing potential (WOCBP) OR is a WOCBP and agrees to not be sexually active or use a highly effective contraceptive method for at least 28 days prior to receiving study treatment, during the treatment period, and for at least 30 days (or local standard of care if longer) after the last dose of study treatment (including the optional cycles)
- Has a negative highly sensitive pregnancy test (urine or serum as required by local regulations) prior to the start of fosaprepitant administration in a given cycle if a WOCBP
- Weighs at least 6 kilograms (kg)
You may not qualify if…
- Will receive stem cell rescue therapy in conjunction with a study-related course of emetogenic chemotherapy or during the 14 days following administration of fosaprepitant
- Is currently a user of any recreational or illicit drugs or has current evidence of drug or alcohol abuse or dependence as determined by the investigator
- Is mentally incapacitated or has a significant emotional or psychiatric disorder that, in the opinion of the investigator, precludes study entry
- Is pregnant or breast feeding
- Is allergic to fosaprepitant, aprepitant, or prescribed 5-HT3 antagonist
- Has an active infection (eg, pneumonia), congestive heart failure, bradyarrhythmia, any uncontrolled disease (eg, diabetic ketoacidosis, gastrointestinal obstruction) except for malignancy, or has any illness which in the opinion of the investigator, might confound the results of the study or pose unwarranted risk in administering study treatment or concomitant therapy to the participant
- Is a WOCBP who has a positive pregnancy test at screening (Cycle 1) or on Day 1 of optional Cycles 2 or 3
- Has been started on systemic corticosteroid therapy within 72 hours prior to study treatment administration or is expected to receive a corticosteroid as part of the chemotherapy regimen. Exceptions apply
- Is taking excluded medications
- Has ever participated in a previous study of aprepitant or fosaprepitant or has taken a non-approved (investigational) drug within the last 4 weeks
- Has a known history of QT prolongation or is taking any medication that is known to lead to QT prolongation
Where it is running
- Phoenix Childrens Hospital ( Site 1101) — Phoenix, Arizona, United States
- Southern California Permanente Medical Group ( Site 1104) — Los Angeles, California, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 1106) — Chicago, Illinois, United States
- Children's Hospitals and Clinics of Minnesota ( Site 1109) — Minneapolis, Minnesota, United States
- St. Jude Children's Research Hospital ( Site 1111) — Memphis, Tennessee, United States
- Athens Childrens Hospital Aglaia Kyriakou ( Site 0101) — Athens, Attica, Greece
- University of Athens - Aghia Sophia Childrens Hospital ( Site 0102) — Athens, Attica, Greece
- University General Hospital of Thessaloniki "AHEPA" ( Site 0103) — Thessaloniki, Greece
- Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi OktatoKorhaz ( Site 0203) — Miskolc, Borsod-Abauj Zemplen county, Hungary
- Szegedi Tudomanyegyetem - Szent-Gyorgyi Albert Klinikai Kozpont ( Site 0201) — Szeged, Csongrád megye, Hungary
- Heim Pal Orszagos Gyermekgyogyaszati Intezet ( Site 0202) — Budapest, Hungary
- LSMUL Kauno Klinikos ( Site 0402) — Kaunas, Lithuania
- Vaiku ligonine VsI VUL Santaros kliniku filialas ( Site 0401) — Vilnius, Lithuania
- Prinses Maxima Centrum ( Site 0501) — Utrecht, Netherlands
- Instituto Nacional de Enfermedades Neoplasicas ( Site 1502) — Lima, Peru
- Clinica Anglo Americana ( Site 1501) — Lima, Peru
- Clinica Delgado ( Site 1503) — Lima, Peru
- Instytut Matki i Dziecka ( Site 0601) — Warsaw, Masovian Voivodeship, Poland
- Instytut Pomnik Centrum Zdrowia Dziecka ( Site 0602) — Warsaw, Masovian Voivodeship, Poland
- Chelyabinsk Regional Children Clinical Hospital ( Site 0705) — Chelyabinsk, Chelyabinsk Oblast, Russia
- Blokhin National Medical Oncology ( Site 0701) — Moscow, Moscow, Russia
- Dmitry Rogachev National Research Center ( Site 0704) — Moscow, Moscow, Russia
- Clinical Research Center of specialized types medical care-Oncology ( Site 0706) — Saint Petersburg, Sankt-Peterburg, Russia
- Leeds Teaching Hospitals NHS Trust ( Site 1002) — Leeds, United Kingdom
- Alder Hey Childrens NHS Foundation Trust Hospital ( Site 1003) — Liverpool, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.